Physician profile
Douglas R Moore
NPI 1265696876
$39,709.54
in general payments reported to CMS, 2019-2025
27 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,751 · 2021: $4,396 · 2022: $3,854 · 2023: $3,469 · 2024: $4,631 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,020 · Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,020.00 |
| Food and Beverage | $1,428.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,238.72 | 2019-2025 | Ofev, Jascayd |
| Genentech USA, INC. | $9,662.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $494.60 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $228.35 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $157.32 | 2024-2025 | |
| Electromed, INC. | $123.16 | 2019-2024 | Smartvest |
| Philips North America LLC | $104.77 | 2019-2025 | Vest Therapy Und |
| Harmony Biosciences LLC | $99.32 | 2023-2025 | Wakix |
| Insmed, INC. | $78.75 | 2021-2025 | Arikayce |
| Genzyme Corporation | $69.29 | 2019-2025 | |
| United Therapeutics Corporation | $65.15 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $49.67 | 2020-2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $44.87 | 2019-2022 | |
| Axsome Therapeutics, INC. | $44.47 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $41.34 | 2023-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.60 | 2020-2024 | Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $21.06 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $20.28 | 2024 | Lumryz |
| Alexion Pharmaceuticals, INC. | $19.40 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $18.18 | 2023 | Acthar |
| La Jolla Pharmaceutical Company | $16.13 | 2019 | |
| Amgen INC. | $15.58 | 2024 | Tezspire |
| Circassia INC. | $15.13 | 2019 | |
| Verona Pharma, INC. | $14.99 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $14.89 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.41 | 2020 | |
| Melinta Therapeutics, LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.